ライフサイエンスコーパス: gonorrhea

1 ach year without increasing the incidence of gonorrhea.

2 nst the global threat of multidrug-resistant gonorrhea.

3 infected adults for syphilis, chlamydia, and gonorrhea.

4 least annually for syphilis, chlamydia, and gonorrhea.

5 ants associated with anorectal chlamydia and gonorrhea.

6 tion, and emergence of extensively-resistant gonorrhea.

7 nge of ailments such as edema, jaundice, and gonorrhea.

8 cies, N. gonorrhoeae, the etiologic agent of gonorrhea.

9 al agent of the sexually transmitted disease gonorrhea.

10 iscuss the development of new treatments for gonorrhea.

11 otic resistance limits treatment options for gonorrhea.

12 tegies to limit the spread of drug-resistant gonorrhea.

13 ures to respond to the threat of untreatable gonorrhea.

14 onitor at-risk individuals for chlamydia and gonorrhea.

15 on should be screened for both chlamydia and gonorrhea.

16 ollowing treatment for pharyngeal and rectal gonorrhea.

17 and 1000 mg) for treatment of uncomplicated gonorrhea.

18 nical trials for treatment of drug-resistant gonorrhea.

19 , herpes simplex virus type 2 detection, and gonorrhea.

20 exually-transmitted diseases (STDs), such as gonorrhea.

21 s test is unsuitable as a screening tool for gonorrhea.

22 ls for treatment of patients with urogenital gonorrhea.

23 innate effectors is a fascinating aspect of gonorrhea.

24 highly effective for treatment of urogenital gonorrhea.

25 d maintaining infection in a murine model of gonorrhea.

26 antibiotics without worsening the burden of gonorrhea.

27 eisseria gonorrhoeae, the causative agent of gonorrhea.

28 ased regimens in the treatment of pharyngeal gonorrhea.

29 treatment failures among MSM diagnosed with gonorrhea.

30 bsence of immunologic memory elicited during gonorrhea.

31 ctam antibiotics as effective treatments for gonorrhea.

32 ossibility that an LOS vaccine might prevent gonorrhea.

33 es the common sexually transmitted infection gonorrhea.

34 ae is an obligate human pathogen that causes gonorrhea.

35 not be used for the detection of pharyngeal gonorrhea.

36 t they are associated with a reduced risk of gonorrhea.

37 eisseria gonorrhoeae, the causative agent of gonorrhea.

38 s crucial to ensure appropriate treatment of gonorrhea.

39 hese 63 women, only 8 (13%) had chlamydia or gonorrhea.

40 ans of antibiotics and the overall burden of gonorrhea.

41 ate for gentamicin's efficacy for pharyngeal gonorrhea.

42 increases in screening and the prevalence of gonorrhea.

43 eisseria gonorrhoeae, the etiologic agent of gonorrhea.

44 Y), active syphilis (4.01 cases/100 PY), and gonorrhea (1.78 cases/100 PY) was higher among women tha

45 427 (48%) participants (1434 chlamydia, 1242 gonorrhea, 252 syphilis).

46 dia frequently coexists with and exacerbates gonorrhea; 2C7-E430G Fc also proved effective against go

47 se screened was syphilis, 7.8% (n = 18/230); gonorrhea, 5.0% urogenital (10/201), 11.1% rectal (18/16

48 hose screened was: syphilis: 7.8%(n=18/230); gonorrhea: 5.0% urogenital(n=10/201), 11.1% rectal(n=18/

49 STIs were syphilis (6574), gonorrhea (64 995), or chlamydia (140 034).

50 tion of repeat positive tests for pharyngeal gonorrhea 7-180 days following treatment among persons r

51 ere higher for women after syphilis (177.3), gonorrhea (73.2), or chlamydia (35.4) compared to women

52 ore likely to test positive for chlamydia or gonorrhea (8.6% vs 4.7% of nonusers; P = .005).

53 ore likely to test positive for chlamydia or gonorrhea (8.6% vs. 4.7% of non-users; p=0.005).

54 cept of a novel therapeutic approach against gonorrhea, a disease rapidly becoming resistant to conve

55 ria gonorrhoeae is the bacterium that causes gonorrhea, a major sexually transmitted disease and a si

56 Gonorrhea, a sexually transmitted disease caused by Neis

57 Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted infection characterize

58 Gonorrhea (adjusted hazard ratio [HR], 3.09 [95% CI, 1.4

59 5% confidence interval {CI}, 1.38-2.97]) and gonorrhea (adjusted RR, 1.66 [95% CI, 1.07-2.60]) were a

60 f those populations at the greatest risk for gonorrhea (adolescents, women, and persons infected with

61 ause our model describes the transmission of gonorrhea among the US MSM population, and, to better ca

62 Gonorrhea, an obligate human infection, is on the rise w

63 Gonorrhea and chlamydia are important causes of pelvic i

64 completing the questionnaire were tested for gonorrhea and chlamydia at this time and also 3 months e

65 ed to have a higher incidence rate than both gonorrhea and chlamydia combined.

66 lification tests are accurate for diagnosing gonorrhea and chlamydia in asymptomatic persons.

67 revious research has supported screening for gonorrhea and chlamydia in asymptomatic, sexually active

68 23 and 22 LHJs provided data on gonorrhea and chlamydia outcomes, respectively.

69 n, increases partner treatment and decreases gonorrhea and chlamydia reinfection rates.

70 eased protection from condom use and reduced gonorrhea and chlamydia risk (p(trend) = 0.032).

71 cer with a Papanicolaou smear, screening for gonorrhea and chlamydia).

72 nd urine nucleic acid amplification test for gonorrhea and chlamydia, rapid plasma reagin for syphili

73 specificity of 97% or greater for diagnosing gonorrhea and chlamydia, regardless of specimen type or

74 enty-one (16.2%) were infected with incident gonorrhea and chlamydia, with no infections among consis

75 y important sexually transmitted infections, gonorrhea and HIV.

76 correlation between the incidence of rectal gonorrhea and human immunodeficiency virus (HIV) infecti

77 nflammation produces the serious sequelae of gonorrhea and increases the probability that N. meningit

78 tion and ciliated cell death associated with gonorrhea and pelvic inflammatory disease.

79 hat cause the sexually transmitted infection gonorrhea and serious bacterial meningitis and septicemi

80 There is an alarming increase of gonorrhea and syphilis among men who have sex with men a

81 There is an alarming increase of gonorrhea and syphilis among men who have sex with men a

82 y of antibiotic usage and resistance against gonorrhea and the consequences of resistance mechanisms

83 The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years

84 ronidazole did not decrease the incidence of gonorrhea and/or chlamydia.

85 The primary outcome was the incidence of gonorrhea and/or chlamydia.

86 elated with the number of cases of syphilis, gonorrhea, and chlamydia (spearman coefficients 0.85, 0.

87 was correlated with the numbers of syphilis, gonorrhea, and chlamydia cases (spearman coefficients 1.

88 pted time series) analysis of STI (syphilis, gonorrhea, and chlamydia) rates before (2000-2012) and a

89 n for conditions other than cervical cancer, gonorrhea, and chlamydia, for which the USPSTF has alrea

90 cancer or condition except cervical cancer, gonorrhea, and chlamydia, which are covered by other USP

91 were very amenable to home screening for BV, gonorrhea, and chlamydia.

92 nt interviews and testing for HIV, syphilis, gonorrhea, and chlamydia.

93 s in the incidence of syphilis among adults, gonorrhea, and congenital syphilis over 11 years in Chin

94 athogens, including measles virus, Neisseria gonorrhea, and human herpesvirus 6, have been described,

95 pened trend was observed in the incidence of gonorrhea, and no trend was observed for the incidence o

96 nts treated with specific antimicrobials for gonorrhea, and trends of these measures over time.

97 t of participants were tested for chlamydia, gonorrhea, and trichomoniasis.

98 Maternal gonorrhea (aOR, 19.5; 95% CI, 2.5-151.3) and higher mate

99 ally representative surveys of chlamydia and gonorrhea are an important measure of disease burden and

100 Safe and effective vaccines against gonorrhea are needed urgently.

101 Additional treatment options for gonorrhea are needed.

102 therapies to counteract multidrug-resistant gonorrhea are urgently needed.

103 erminants of risk for STI acquisition, using gonorrhea as an index infection.

104 n appropriate control strategy for anorectal gonorrhea, as few infections would be missed.

105 0% effective for treatment of culture-proven gonorrhea at genital, oral, and rectal sites of infectio

106 inical trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes in

107 cing of urine samples from men with urethral gonorrhea can recover near-complete N. gonorrhoeae genom

108 e life span of antibiotics and the number of gonorrhea cases expected under current and alternative s

109 ly treating an additional 91.1 (54.3, 127.3) gonorrhea cases per 100,000 MSM population each year wit

110 .1 (95% uncertainty interval: [47.7, 111.9]) gonorrhea cases per 100,000 MSM population each year wit

111 gh gonorrhea is on the rise with >550 000 US gonorrhea cases reported to the Centers for Disease Cont

112 Of all anorectal chlamydia/gonorrhea cases, 72% (n = 92)/33% (n = 4) were diagnosed

113 timated prevalence of gonorrhea, the rate of gonorrhea cases, and the proportion of cases presenting

114 pulation but 66.9% of chlamydia and 42.9% of gonorrhea cases.

115 Gonorrhea, caused by the bacterium Neisseria gonorrhoeae

116 transmitted infections (STIs; eg, syphilis, gonorrhea, chlamydia) each year, with commercial sex int

117 iasis, other intestinal parasites, syphilis, gonorrhea, chlamydia, and human immunodeficiency virus,

118 In 924 FSWs, the prevalence of HIV, gonorrhea, chlamydia, and syphilis titers > or =1:8 was

119 ct after sexual assault; empiric therapy for gonorrhea, chlamydia, and trichomoniasis based on update

120 STI screening for syphilis AND gonorrhea/chlamydia at all anatomic sites and positivity

121 STI screening (syphilis and gonorrhea/chlamydia at all anatomic sites) and positivit

122 sers be screened biannually for syphilis and gonorrhea/chlamydia at all anatomic sites.

123 sers be screened biannually for syphilis and gonorrhea/chlamydia at all anatomic sites.

124 screening was lower and syphilis and rectal gonorrhea/chlamydia positivity was higher.

125 lower and positivity for syphilis and rectal gonorrhea/chlamydia was higher.

126 hilis, urogenital, rectal, and oropharyngeal gonorrhea/chlamydia, respectively.

127 hilis, urogenital, rectal, and oropharyngeal gonorrhea/chlamydia, respectively.

128 c also proved effective against gonorrhea in gonorrhea/chlamydia-coinfected mice.

129 and 34.9-fold higher unadjusted incidence of gonorrhea compared to those without HIV.

130 ria gonorrhoeae, the sole causative agent of gonorrhea, constitutively undergoes diversification of t

131 improvements in treatment as prevention and gonorrhea control can negatively impact the correlation

132 re, thus potentially improving chlamydia and gonorrhea control efforts.

133 ntial component of an integrated approach to gonorrhea control.

134 crobial classes challenges this component of gonorrhea control.

135 Evaluations of potential new treatments for gonorrhea currently make limited use of new understandin

136 oportion of men treated with penicillins for gonorrhea declined from 39.5% in 1988 to 0% in 1994, whi

137 Gonorrhea diagnosis rates in the United States increased

138 Limiting PrEP to 1 year after syphilis or gonorrhea diagnosis would cost $963 847 334, but only 14

139 oses were within 2 years after a syphilis or gonorrhea diagnosis.

140 the predilection to test and probability of gonorrhea disease.

141 Pharyngeal and rectal gonorrhea DNA persisted in 8% of men 14 days after treat

142 For rectal gonorrhea, DNA positivity was present in 6% (95% CI, 1.4

143 The mucosal Ig response apparent during gonorrhea does not correlate with that observed systemic

144 alysis of patients diagnosed with pharyngeal gonorrhea during 1993-2011, at a sexually transmitted di

145 cause of the sexually transmitted infection gonorrhea, elicits low levels of specific Ig that declin

146 infection, and to co-treat individuals with gonorrhea for chlamydia.

147 tive urinalysis biosensor to monitor UTI and gonorrhea from human urine.

148 Gonorrhea (GC) and chlamydia (CT) are the most commonly

149 Although chlamydia (CT) and gonorrhea (GC) infections are increasing in the United S

150 Although chlamydia (CT) and gonorrhea (GC) infections are increasing in the United S

151 or simultaneous detection of chlamydia (CT), gonorrhea (GC), and trichomonas (TV).

152 e samples from men with symptomatic urethral gonorrhea, >=92.8% coverage of an N. gonorrhoeae referen

153 Treatment for gonorrhea has been complicated by antimicrobial resistan

154 erculosis, malaria, Staphylococcus aureus or gonorrhea has led to rapidly increasing population level

155 agent of the sexually transmitted infection, gonorrhea, has developed resistance to most conventional

156 eisseria gonorrhoeae, the causative agent of gonorrhea, has evolved several mechanisms to subvert com

157 acid amplification test-diagnosed pharyngeal gonorrhea in a single-arm, unblinded clinical trial.

158 ith men (MSM) with NAAT-diagnosed pharyngeal gonorrhea in a single-arm, unblinded clinical trial.

159 than culture for the detection of pharyngeal gonorrhea in at-risk patients.

160 n plus 2 g azithromycin for the treatment of gonorrhea in cephalosporin-allergic patients.

161 in plus 2g azithromycin for the treatment of gonorrhea in cephalosporin-allergic patients.

162 Results for gonorrhea in females demonstrated sensitivities for endo

163 ; 2C7-E430G Fc also proved effective against gonorrhea in gonorrhea/chlamydia-coinfected mice.

164 -identified race (STC-2), and local rates of gonorrhea in men (STC-3).

165 ended screening guidelines for chlamydia and gonorrhea in men and women in the United States?

166 its and harms of screening for chlamydia and gonorrhea in men.

167 The USPSTF recommends screening for gonorrhea in sexually active females aged 24 years or yo

168 who were tested for syphilis, chlamydia, and gonorrhea in the past 12 months by year and stratified b

169 Genomic epidemiology studies of gonorrhea in the United States have primarily focused on

170 help develop a more complete epidemiology of gonorrhea in the United States.

171 t fully reflect trends for all patients with gonorrhea in the United States.

172 gonorrhea infection, trends in chlamydia and gonorrhea in the Veterans Health Administration (VHA) sy

173 Acute gonorrhea in women is characterized by a mucopurulent ex

174 sentinel clinics, and incidence of reported gonorrhea in women, both measured at the community level

175 k between biofilm formation and asymptomatic gonorrhea in women.

176 HIV incidence was predicted using rectal gonorrhea incidence as the determinant in regression ana

177 alth Organization's (WHO) target of reducing gonorrhea incidence by 90% during 2018-2030, by comparin

178 The observed correlation suggest that rectal gonorrhea incidence can potentially serve as a predictor

179 rkov chain Monte Carlo methods, we fitted to gonorrhea incidence in 2008-2017, then used Bayesian for

180 Chlamydia test positivity and gonorrhea incidence in women decreased over the study pe

181 e and decrease chlamydia test positivity and gonorrhea incidence in women.

182 Gonorrhea incidence is increasing rapidly in many countr

183 ce ratio = 0.89, 95% CI 0.77-1.04, p = 0.15; gonorrhea incidence rate ratio = 0.91, 95% CI .71-1.16,

184 Chlamydia and gonorrhea incidence rates in persons with HIV were 1,432

185 Chlamydia and gonorrhea incidence rates were calculated each year by d

186 rgeting strategy, could substantially reduce gonorrhea incidence, despite antibiotic resistance.

187 % reduction in both chlamydia positivity and gonorrhea incidence, though the confidence bounds on the

188 sets of selective testing criteria (STC) for gonorrhea, incorporating risk factors identified using l

189 Overall testing for chlamydia and gonorrhea increased from 22% to 42% (PTREND < .01), and

190 d vaginal pH (87% versus 48%; P < 0.001) and gonorrhea infection (15% versus 4%; P = 0.002).

191 tant role in the pathogenesis of symptomatic gonorrhea infection and that alterations in lipid A bios

192 vicemembers have high rates of chlamydia and gonorrhea infection, trends in chlamydia and gonorrhea i

193 One hundred pharyngeal and 100 rectal gonorrhea infections in 190 men were included.

194 rhoeae-spiked urine samples and samples from gonorrhea infections to determine optimal DNA extraction

195 30 (21.8%) and 108/840 (12.9%) chlamydia and gonorrhea infections, respectively, were identified.

196 matis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) infections in women.

197 Prevention and control of gonorrhea is an important public health concern due to t

198 The hallmark of gonorrhea is an intense inflammatory response that is ch

199 Acute gonorrhea is characterized by neutrophilic inflammation

200 ncidence of the sexually transmitted disease gonorrhea is expected to rise due to the spread of Neiss

201 city of urine-based assays for chlamydia and gonorrhea is limited, and the possible misclassification

202 A safe and effective vaccine against gonorrhea is needed because of emerging resistance of go

203 navailable clinical laboratory AST, although gonorrhea is on the rise with >550 000 US gonorrhea case

204 Gonorrhea is the second most commonly reported notifiabl

205 Gonorrhea is the second most commonly reported notifiabl

206 tamicin alone in the treatment of pharyngeal gonorrhea is uncertain.

207 o causes long-term sequelae, but the role of gonorrhea is unclear.

208 Gonorrhea is usually empirically treated, with no AST re

209 eisseria gonorrhoeae, the causative agent of gonorrhea, is an exclusive human pathogen whose growing

210 eisseria gonorrhoeae, the etiologic agent of gonorrhea, is frequently asymptomatic in women, often le

211 agent of the sexually transmitted infection gonorrhea, is not preventable by vaccination and is rapi

212 Neisseria gonorrhoeae, which causes gonorrhea, is particularly adept at driving HIV-1 expres

213 tested 96 urine samples collected along with Gonorrhea Isolate Surveillance Project (GISP) urethral s

214 smitted infections (STIs) chlamydia (CT) and gonorrhea (NG) are often asymptomatic in women and undet

215 e used in conjunction with routine chlamydia/gonorrhea nucleic acid-based screening are likely to hav

216 In 2019, testing for chlamydia and gonorrhea occurred in 2.3% of patients, 22.6% of women a

217 were independently associated with anorectal gonorrhea (odds ratios [ORs], 3.3 [95% confidence interv

218 Gonorrhea often occurs as a coinfection with human immun

219 acterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition agains

220 However, conjunctivitis caused by gonorrhea or chlamydia and conjunctivitis in contact len

221 Among females with a history of gonorrhea or chlamydia in the previous 12 months, chlamy

222 Heterosexual individuals with gonorrhea or chlamydial infection were eligible for the

223 women following first diagnosis of syphilis, gonorrhea, or chlamydia during 2000-2015.

224 A positive syphilis, gonorrhea, or chlamydia test was significantly associate

225 rt study of adults diagnosed with chlamydia, gonorrhea, or syphilis in Kaiser Permanente Southern Cal

226 primary outcome was incidence of chlamydia, gonorrhea, or syphilis.

227 .04), and less likely to report a history of gonorrhea (P = .04).

228 es resistant to antimicrobials used to treat gonorrhea, percentage of patients treated with specific

229 then tested 100 urine specimens, known to be gonorrhea positive by nucleic acid amplification testing

230 Overall anorectal chlamydia/gonorrhea positivity was 13.4% (n = 127)/1.3% (n = 12).

231 For pharyngeal gonorrhea, positivity of N. gonorrhoeae DNA on both PCR

232 ctal screening with respect to chlamydia and gonorrhea prevalence and risk factors.

233 To measure chlamydia and gonorrhea prevalence in the United States.

234 e impact of safe behavior on the dynamics of gonorrhea prevalence.

235 treatment recommendations for chlamydia and gonorrhea; prevention and screening recommendations for

236 sible for the sexually transmitted infection gonorrhea, protects against exogenous induction of apopt

237 N. gonorrhoeae, while commercially available gonorrhea rapid kit showed a detection limit of 10(6) CF

238 U.S. gonorrhea rates are rising, and antibiotic-resistant Nei

239 e results suggest that observed increases in gonorrhea rates could be explained by both increases in

240 7-1.264; P < .001) increases in syphilis and gonorrhea rates, respectively, and a 12% reduction in ch

241 Gonorrhea remains a major public health challenge, and c

242 evidence for screening men for chlamydia and gonorrhea remains insufficient at this time, all sexuall

243 Gonorrhea remains one of the most frequent infectious di

244 e scenario, and by 75% if > 70% of resistant gonorrhea remains treatable.

245 y transmitted diseases such as chlamydia and gonorrhea requires systemic treatment in addition to top

246 The incidence of chlamydia and gonorrhea rose dramatically from 2009-2019.

247 ype, as recommended by the CDC for chlamydia/gonorrhea screening among women.

248 the recommended specimen type for chlamydia/gonorrhea screening.

249 omplement contact tracing for reconstructing gonorrhea sexual networks, the concordance between the N

250 cing of urine samples from men with urethral gonorrhea, sufficient data can be obtained to reconstruc

251 Strengthening the U.S. Response to Resistant Gonorrhea (SURRG).

252 ally transmitted infections (STIs) including gonorrhea, syphilis, chlamydia, and trichomoniasis, is i

253 lly transmitted infections (STIs), including gonorrhea, syphilis, chlamydia, and trichomoniasis, is i

254 heir HIV diagnosis, 28.5% had a diagnosis of gonorrhea, syphilis, or chlamydia at any visit.

255 es in the annual percentages of men with >=1 gonorrhea test and men with >=1 positive gonorrhea test

256 alculated annual percentages of men with >=1 gonorrhea test and men with >=1 positive result, among m

257 e was a significant increase in men with >=1 gonorrhea test from 2010 (3.1%) to 2017 (6.4%; adjusted

258 >=1 gonorrhea test and men with >=1 positive gonorrhea test result between 2010 and 2017.

259 temporal trends in syphilis, chlamydia, and gonorrhea testing among sexually active HIV-infected adu

260 VHA-wide adherence to chlamydia and gonorrhea testing in high-risk groups merits improvement

261 We sought to evaluate changes in gonorrhea testing patterns and positivity among men in M

262 To guide interpretation of gonorrhea tests of cure using nucleic acid amplification

263 ight critical questions in the management of gonorrhea that can be addressed by mathematical models a

264 ted the model to the estimated prevalence of gonorrhea, the rate of gonorrhea cases, and the proporti

265 ge transmission clusters were susceptible to gonorrhea therapies, suggesting that resistance to empir

266 antimicrobial agents has reduced options for gonorrhea therapy worldwide.

267 effects to expect a highly efficacious anti-gonorrhea therapy.

268 eration of new designs for the evaluation of gonorrhea therapy.

269 ty trials designed to seek an indication for gonorrhea therapy.

270 ines are likely partially protective against gonorrhea, this has renewed interest in a gonococcal vac

271 herapy with ceftriaxone and azithromycin for gonorrhea to ensure effective treatment and slow emergen

272 loped and calibrated a mathematical model of gonorrhea transmission among men who have sex with men (

273 An SIS/SAS model of gonorrhea transmission in a population of highly active

274 A mathematical model describing gonorrhea transmission incorporated resistance emergence

275 on process for antimicrobials for urogenital gonorrhea treatment and encourages the consideration of

276 h challenge, and current recommendations for gonorrhea treatment are threatened by evolving antimicro

277 Empirical gonorrhea treatment at initial diagnosis reduces onward

278 Gonorrhea treatment has been complicated by antimicrobia

279 rol and Prevention guidelines for pharyngeal gonorrhea treatment recommend dual therapy with intramus

280 ed to find alternative approaches to current gonorrhea treatment such as vaccine development or novel

281 n resistance has declined in the years since gonorrhea treatment with penicillin was discontinued.

282 d the usefulness of existing antibiotics for gonorrhea treatment, but ongoing monitoring of resistanc

283 the last antibiotic recommended for empiric gonorrhea treatment, poses an urgent public health threa

284 f infection and is a promising new agent for gonorrhea treatment.

285 e is the foundation of currently recommended gonorrhea treatment.

286 similar to the antibiotics commonly used in gonorrhea treatment.

287 with men diagnosed with pharyngeal or rectal gonorrhea underwent swabbing from the pharynx or rectum

288 ning drugs, like auranofin, for treatment of gonorrhea warrants further investigation.

289 2019 incidence of chlamydia and gonorrhea was 100.8 and 56.3 cases per 100,000 VHA users

290 Tests and cases of chlamydia and gonorrhea were defined based on lab results in the elect

291 A total of 1440 cases of pharyngeal gonorrhea were diagnosed during the study period, 25% of

292 ears diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 24

293 sseria gonorrhoeae is the etiologic agent of gonorrhea, which has been among the most frequently repo

294 ndings may help to improve animal models for gonorrhea while also having implications in the choice o

295 idating the correlates of protection against gonorrhea will inform the development of Ab-based gonoco

296 Clinicians should use caution when treating gonorrhea with CDC's current alternative regimen (gentam

297 perform well for detection of chlamydia and gonorrhea with self-obtained vaginal swabs shipped in a

298 Clinicians should use caution when treating gonorrhea with the CDC's current alternative regimen (ge

299 herapeutic and prophylactic strategy against gonorrhea, with implications for the development of an e

300 PrEP to all women diagnosed with syphilis or gonorrhea would cost $7 371 111 000 and could have preve